Alyeska Investment Group L.P. bought a new position in shares of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 80,000 shares of the company’s stock, valued at approximately $1,351,000. Alyeska Investment Group L.P. owned approximately 0.26% of Clementia Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CMTA. Birchview Capital LP acquired a new position in shares of Clementia Pharmaceuticals during the third quarter worth $372,000. Victory Capital Management Inc. acquired a new stake in Clementia Pharmaceuticals in the third quarter valued at $520,000. Citadel Advisors LLC acquired a new stake in Clementia Pharmaceuticals in the third quarter valued at $2,061,000. Sphera Funds Management LTD. acquired a new stake in Clementia Pharmaceuticals in the third quarter valued at $2,753,000. Finally, JPMorgan Chase & Co. acquired a new stake in Clementia Pharmaceuticals in the third quarter valued at $10,937,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price target on shares of Clementia Pharmaceuticals in a report on Tuesday, November 14th. BTIG Research assumed coverage on shares of Clementia Pharmaceuticals in a report on Thursday, August 31st. They issued a “buy” rating and a $32.00 price target on the stock. Leerink Swann assumed coverage on shares of Clementia Pharmaceuticals in a report on Monday, August 28th. They issued an “outperform” rating and a $23.00 price target on the stock. Finally, Morgan Stanley assumed coverage on shares of Clementia Pharmaceuticals in a report on Monday, August 28th. They issued an “overweight” rating and a $27.00 price target on the stock.

Shares of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) opened at $16.68 on Friday. Clementia Pharmaceuticals Inc. has a twelve month low of $15.05 and a twelve month high of $18.95.

COPYRIGHT VIOLATION NOTICE: “Alyeska Investment Group L.P. Buys New Stake in Clementia Pharmaceuticals Inc. (CMTA)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/12/15/alyeska-investment-group-l-p-buys-new-stake-in-clementia-pharmaceuticals-inc-cmta.html.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Institutional Ownership by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.